Q2 · MEDICINE
Article
Author: Suryakirian, Pemmaraju V ; Struyf, Frank ; Durando, Paolo ; Esposito, Susanna ; Supparatpinyo, Khuanchai ; Behre, Ulrich ; Ferguson, Murdo ; McNeil, Shelly A ; Janssens, Michel ; Hillemanns, Peter ; Folschweiller, Nicolas ; Peters, Klaus ; Ferguson, Linda ; Dionne, Marc ; Moris, Philippe ; Decreux, Annabelle ; Poncelet, Sylviane ; Schwarz, Tino F ; Ramjattan, Brian
AbstractThis analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9–14 years or following 3 doses in women aged 15–25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.